Current multiple myeloma treatment strategies with novel agents: a European perspective.

Details

Ressource 1Download: BIB_6C9646C3771B.P001.pdf (918.62 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_6C9646C3771B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Journal
Oncologist
Author(s)
Ludwig Heinz, Beksac Meral, Blade Joan, Boccadoro Mario, Cavenagh Jamie, Cavo Michele, Dimopoulos Meletios, Drach Johannes, Einsele Hermann, Facon Thierry, Goldschmidt Hartmut, Harousseau Jean-Luc, Hess Urs, Ketterer Nicolas, Kropff Martin, Mendeleeva Larisa, Morgan Gareth, Palumbo Antonio, Plesner Torben, San Miguel Jesus, Shpilberg Ofer, Sondergeld Pia, Sonneveld Pieter, Zweegman Sonja
ISSN
1549-490X[electronic], 1083-7159[linking]
Publication state
Published
Issued date
2010
Volume
15
Number
1
Pages
6-25
Language
english
Abstract
The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.
Keywords
Multiple Myeloma, Thalidomide, Bortezomib, Lenalidomide, Stem-Cell Transplantation, Lenalidomide Plus Dexamethasone, Newly-Diagnosed Myeloma, Velcade-Thalidomide-Dexamethasone, Bone-Marrow-Transplantation, Randomized Controlled-Trial, Progression-Free Survival, Impaired Renal-Function, High Response Rates, Long-Term Survival
Pubmed
Web of science
Open Access
Yes
Create date
24/02/2010 9:50
Last modification date
20/08/2019 14:26
Usage data